Human Cardiac Troponin I ELISA Kit, Fluorescent

Cardiac Troponin I in vitro CatchPoint SimpleStep ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of Cardiac Troponin I protein in human serum, plasma, cell culture supernatants, and cell and tissue extracts.

This CatchPoint SimpleStep ELISA kit has been optimized for Molecular Devices Microplate Readers. Click here for a list of recommended Microplate Readers.
If using a Molecular Devices' plate reader supported by SoftMax® Pro software, a preconfigured protocol for these CatchPoint SimpleStep ELISA Kits is available with all the protocol and analysis settings at www.softmaxpro.org.

The CatchPoint SimpleStep ELISA employs an affinity tag labeled capture antibody and a reporter conjugated detector antibody which immunocapture the sample analyte in solution. This entire complex (capture antibody/analyte/detector antibody) is in turn immobilized via immunoaffinity of an anti-tag antibody coating the well. To perform the assay, samples or standards are added to the wells, followed by the antibody mix. After incubation, the wells are washed to remove unbound material. CatchPoint HRP Development Solution containing the Stoplight Red Substrate is added. During incubation, the substrate is catalyzed by HRP generating a fluorescent product. Signal is generated proportionally to the amount of bound analyte and the intensity is measured in a fluorescence plater reader at 530/570/590 nm Excitation/Cutoff/Emission.

The regulatory troponin complex regulates skeletal and cardiac muscle contraction. This complex, together with tropomyosin, is located on the actin filament and it is composed of three protein subunits: troponin T (the tropomyosin-binding subunit), troponin I (the inhibitory subunit, which inhibits the ATPase activity of acto-myosin), and troponin C (the Ca2+-binding subunit). Troponins T and I have unique cardiac isoforms, whereas cardiac and skeletal muscle share troponin C. Specifically, three human troponin I isoforms have been described: one is expressed in cardiac muscle (Cardiac Troponin I) and the other two are found in slow-twitch and fast-twitch skeletal muscle fibers (slow sTnI and fast sTnI, respectively). The overlap in sequence between Cardiac Troponin I and slow sTnI is approximately 40% and somewhat less for fast sTnI. Cardiac Troponin I is 209 amino acid long with a molecular weight of approximately 24 kDa. Mouse and rat Cardiac Troponin I proteins both show 93% amino acid identity to human Cardiac Troponin I.The presence of human Cardiac Troponin I in serum (together with chest pain and electrocardiographic changes) is now considered as one highly specific biochemical marker of myocardial injury, risk stratification of acute coronary syndrome and myocardial infarction. Mutations of Cardiac Troponin I are associated with hereditary cardiomyopathy. Specifically, defects in Cardiac Troponin I are the cause of cardiomyopathy familial hypertrophic type 7 (CMH7). Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intra-familial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death. Defects in Cardiac Troponin I also cause cardiomyopathy familial restrictive type 1 (RCM1). RCM1 is a heart muscle disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function. Furthermore, cardiomyopathy dilated type 2A (CMD2A) and cardiomyopathy dilated type 1FF (CMD1FF), disorders characterized by ventricular dilation and impaired systolic function resulting in congestive heart failure and arrhythmia, are caused by defects in Cardiac Troponin I.

Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.